Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Critical Mineral Executive Order Issued by President Donald Trump (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:BCRX)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 6, 2025

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

GlobeNewswire February 24, 2025

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

GlobeNewswire February 24, 2025

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire February 19, 2025

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

GlobeNewswire February 12, 2025

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

GlobeNewswire February 10, 2025

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

GlobeNewswire February 10, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 4, 2025

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

GlobeNewswire January 10, 2025
View More News ››

Opinion & Analysis (NDAQ:BCRX)

The Calandra Report: Blood in streets, rivers of fortune

Thom Calandra July 24, 2015

The Calandra Report: Rapivab, MERS, Thailand & BCRX

Thom Calandra June 19, 2015

The Calandra Report: Show me a favorite, I dare you

Thom Calandra June 8, 2015

The Calandra Report: Moveable feast of pharma, not gold

Thom Calandra June 4, 2015

The Calandra Report: They're jamming In the name of the lode

Thom Calandra March 13, 2015

Ultra-Actionables: Natcore Tech, Angkor Gold, BioCryst, Vegas

Thom Calandra February 20, 2015
View More Opinion ››

Bullboard Posts (NDAQ:BCRX)

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

NEWS: $BCRX Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today2025-02-24 18:15:51 ET Investors clearly weren't in a forgiving...
whytestocks - February 24, 2025

BioCryst Announces Positive Results from APeX-P Trial for OR

BREAKING NEWS: $BCRX BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO&#xAE; (berotralstat) in Pediatric Patients...
whytestocks - February 24, 2025

BioCryst Reports Third Quarter 2024 Financial Results and Pr

NEWS: $BCRX BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update@ Q3 2024 ORLADEYO net revenue of $116.3...
whytestocks - November 4, 2024

BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Ou

JUST IN: $BCRX BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance | BenzingaMonday...
whytestocks - May 6, 2024

BioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue Estim

Just In: $BCRX BioCryst Pharmaceuticals Reports Q1 Loss, Tops Revenue Estimates | BenzingaBioCryst Pharmaceuticals (NASDAQ: BCRX) came...
whytestocks - May 6, 2024

4 PROMISING BIOTECH STOCKS WITH IMMENSE POTENTIAL!

$BCRX $IPSC $DYAI $CDNA   Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of...
AviseAnalytics - January 14, 2022
View more Bullboard ››

Desert Gold Ventures Inc.

Desert Gold Ventures Inc.

Desert Gold Ventures Inc. is a gold exploration and development company which controls the approximately 440 square ...
View More »